Feb. 23 at 5:42 PM
$ALT Oh Billy Irish, you continue to fall short of expectations and continue to share misleading information.
What the article said (in order):
1)
$IVA -
"Inventiva’s upcoming Phase III readout for pan-PPAR agonist lanifibranor is “the biggest event in the MASH space” this year, according to Nash."
2)
$VKTX -
"Viking Therapeutics has long attracted significant interest from Big Pharma. With pipeline assets that target both obesity and MASH, analysts have marked the biotech as one likely to draw suitors.
3)
$ALT -
"Altimmune’s pemvidutide stands apart from others in the MASH pipeline due to its ability to preserve lean muscle mass, as well as ensuring MASH resolution and weight loss, a company spokesperson told BioSpace in an email."
4)
$SGMT -
Like pemvidutide, Sagimet Biosciences’ denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor that blocks the production of new fat in the liver, holds FDA Breakthrough Therapy Designation in MASH.
Do Better Desperate
$ALT Pumper Billy.
